Sales at his pharma outfit Wockhardt were hit by a USFDA import ban on drugs made at two of the company's factories in Maharashtra and by import alerts issued by UK's health regulator. In fiscal year 2014, the company reported a 14 percent drop in revenues to $810 million while net profits nearly halved to $140 million. Despite setbacks, Wockhardt's shares are up by 50 percent in the past 11 months restoring his billionaire status.